Nicotine is the addictive compound in tobacco products which exerts psychosomatic effects that contribute to abuse and to low rates of abstinence in treatment-seeking smokers. At present, the most successful smoking cessation aide helps one in four individuals quit smoking at 1 year postcessation. New adjunctive therapies are needed to improve status of smoking-related public health crises, and β-lactam antibiotics are one class of potential therapies as they favorably augment extrasynaptic glutamate clearance. Our study used two-chamber place conditioning to assess effects of ceftriaxone (CTX) on persistence of conditioned nicotine reward. Rats were conditioned to associate nicotine (0.4 mg/kg, subcutaneous) with one context and vehicle with an alternative context. After initial post-test, rats received either daily ceftriaxone (200 mg/kg, intraperitoneal) or saline. All rats showed nicotine place preference during post-test 1. CTX-treated rats meeting extinction criterion by post-test 7 showed significantly reduced preference for the nicotine-paired context during post-test 2 compared with vehicle-treated rats. We interpret these data to support the further study of CTX as a smoking cessation aide. Our results suggest that CTX reduces persistence of conditioned nicotine reward and may be helpful for improving abstinence rates in a subset of treatment-seeking smokers. Behavioural Pharmacology 28: [485][486][487][488]
Introduction
Nicotine is an ingredient in tobacco products that has rewarding and reinforcing properties that contribute to its abuse. Mechanistically, nicotine binds to nicotinic acetylcholine receptors (nAChRs) comprised homopentamerically (α7) and heteropentamerically (e.g. α4β2) (Cooper et al., 1991) (for review, see Gotti et al., 2006) . Desensitization and upregulation of β2 subunit-containing nAChRs is evident following chronic nicotine use (Fenster et al., 1997 (Fenster et al., , 1999 Cosgrove et al., 2009) , and upregulation of β2 subunit-containing nAChRs persists throughout and underlies symptoms of nicotine withdrawal (for review, see Simmons and Gould, 2014) . The most effective smoking cessation aides, including varenicline and nicotine replacement therapies, bind in part to β2 subunit-containing nAChRs to relieve symptoms emerging during nicotine withdrawal but only help about one in four treatmentseeking smokers successfully quit at 1 year postcessation Jorenby et al., 2006; Nides et al., 2006) . Although a half-century of research has rightfully been allocated to nAChR agonist-based therapies, alternative transmitter and peptide systems become dysregulated following chronic nicotine use, the receptors of which may be viable targets for pharmacotherapeutic intervention.
Chronic nicotine downregulates levels of astrocytic glutamate transporter 1 [GLT1; also known as excitatory amino acid transporter 2 (EAAT2)] within neuronal structures known to process reward and mediate relapse propensity (Knackstedt et al., 2009) . Impaired extrasynaptic glutamate clearance can lead to neuronal death and is a pathophysiological hallmark of numerous central nervous system diseases including substance use disorders. A seminal report found that ceftriaxone, a widely available β-lactam antibiotic, facilitates functional extrasynaptic glutamate clearance by upregulating membranal GLT1 (Rothstein et al., 2005) . Throughout the recent decade, ceftriaxone (CTX) has been shown to reduce levels of self-administered nicotine (Sari et al., 2016) , prevent tolerance to nicotine-associated analgesia (Schroeder et al., 2011) , and attenuate drug-primed reinstatement of nicotine place preference (Alajaji et al., 2013) . CTX thus appears to normalize dysregulated central glutamate transmission after chronic nicotine use and in turn normalize otherwise aberrant addictionrelated behaviors.
The present study was conducted to investigate the potential therapeutic benefit of CTX by examining effects on persistence of conditioned nicotine reward. The results demonstrate that, whereas vehicle-treated control rats repeatedly show preference for a nicotinepaired context, CTX prevents repeated nicotine place Supplemental digital content is available for this article. Direct URL citations appear in the printed text and are provided in the HTML and PDF versions of this article on the journal's website (www.behaviouralpharm.com).
preference in rats that fully extinguish by post-test 7. These results suggest that CTX may facilitate reward devaluation or enhance extinction of a nicotine-paired context.
Methods

Subjects
Adult male Sprague-Dawley rats were purchased from Charles River Laboratories (Malvern, Pennsylvania, USA) and adjusted to Temple University's rat vivarium for 1 week before beginning experiments. Rats were housed in a temperature-controlled and humiditycontrolled vivarium, and were kept under a 12-h : 12-h light-dark cycle with lights turning on daily at 09:00 h. Rats were pair-housed and given food and water without restriction except during place preference conditioning or testing sessions. All procedures were approved by Temple University's Institutional Animal Care and Use Committee.
Apparatus, groups, and procedure
For place conditioning, a two-chamber apparatus with distinguishing visual and tactile cues was used. The experimental timeline can be found in Fig. 1a . An initial 15 min pretest was conducted to establish baseline preference for each of two chambers. Twenty-four hours following pretest, rats had four consecutive 20-min conditioning days where contexts were paired either with sterile water (preferred side) or nicotine (0.4 mg/kg, subcutaneous; nonpreferred side). For all rats, sterile water was given during the morning session (∼10:00 -12:00-h) and nicotine was given during the afternoon session (∼14:00 -6:00-h). During conditioning, rats were confined to one of the two chambers. After conditioning, a series of 15 min post-tests, spaced 72 h apart, were conducted. During post-tests, rats freely shuttled between contexts and amount of time within each context was quantified for analysis. After post-test 1, rats were divided into two treatment groups (n = 8/group): one group received CTX (200 mg/kg, intraperitoneal) in the homecage ∼ 2 h following post-test whereas the other received saline (VEH) as control. The dose of CTX was selected on the basis of seminal work showing that repeated administration at 200 mg/kg yields brain levels sufficient to upregulate GLT1 (Rothstein et al., 2005) .
Analyses
For place conditioning, post-test data are expressed as conditioned place preference (CPP) score [post-test time (s) in nicotine-paired context minus pretest time (s) in nicotine-paired context] as in previous reports (Le Foll and Goldberg, 2005; Gregg et al., 2016; Kim et al., 2016a, b) ]. Independent sample t-tests were used to compare CPP scores between CTX and VEH groups for post-tests 1 and 2. Comparisons were made between all rats as well as on subpopulations that were fully extinguished by post-test 7. In addition, comparisons were performed between each group's CPP score and '0' -the point of no-change -during post-test 1 to assess for initial nicotine place preference. Four rats were excluded from analysis as their pretest score showed greater than or equal to 90% preference for one of the two contexts. Rats were considered to have extinguished place preference when the CPP score for posttests 2 + was 20% or less of the CPP score for post-test 1, similar to the criterion used before (Berry et al., 2012) . Rats were ran during post-tests until the extinction criterion was reached, and the type I error rate (α) was established at 0.05.
Results
CTX and VEH groups showed significantly greater CPP score compared with '0' during post-test 1, indicating a significant initial nicotine place preference [all |t(5)| ≥ 6.90, P < 0.01; Fig. 1b, upper-right panel] . During post-test 2, 50% of CTX-treated rats extinguished place preference, whereas no VEH-treated rats reached extinction (Fig. 1b, left panel) . Independent sample t-tests revealed no difference between CTX and VEH groups during post-test 1 (|t(9)| = 1.18, NS). During post-test 2, analyses on all rats revealed no significant difference in CPP score [|t(14)| = 0.12, NS]. Notably, in the subset of rats that eventually extinguished nicotine place preference, CTX treatment significantly reduced CPP score relative to VEH-treated control rats [|t-(9)| = 2.33, P < 0.05; Fig. 1b, bottom-right panel] . All pretest and post-test CPP scores can be found in Supplemental Table 1 (Supplemental digital content 1, http://links.lww.com/BPHARM/A13).
Discussion
In a seminal report detailing potential therapeutic utility of CTX for nicotine dependence, Alajaji et al. (2013) observed that CTX did not disrupt the development of nicotine place preference, an effect additionally observed by our research group (Philogene-Khalid HL and Rawls SM, unpublished data), but attenuated nicotine-primed reinstatement of place preference for a nicotine-paired context. In addition, the authors found that CTX attenuated anxiety-like behavior and somatic withdrawal signs in tests of precipitated nicotine withdrawal in mice. Our results converge with these previous studies to endorse the utility of CTX to treat nicotine dependence by attenuating withdrawal signs, reducing relapse propensity and facilitating extinction of a nicotine-paired context. Although our place conditioning apparatus tends to imbue a bias toward one side, we anticipate comparable results with unbiased place conditioning, as CTX is likely affecting the strength of nicotine preference, which can be established using either place conditioning design. From our results, it is clear that CTX is efficacious in some but not all rats. At present, we speculate that sensitivity to CTX treatment may be due to its augmentation of membranal GLT1 in structures that process reward. Determining neurobiological differences between 'treatment-sensitive' and 'treatment-resistant' subpopulations will be important to inform clinical study of putative β-lactam pharmacotherapies for smoking cessation in treatment-seeking smokers.
The ubiquitous effect of stimulant drugs on dysregulating glutamate transmission in brain reward structures has yielded decades of intensive research. Only recently, however, are widely available β-lactam antibiotics and β-lactamase inhibitors being considered for treating substance use disorders. Typically, CTX is prescribed (∼25 mg/kg, intraperitoneal, for 10 days) for treating bacterial infection. Multiple preclinical reports show that 100-200 mg/kg CTX (intraperitoneal) yields significant effects on augmenting glutamate neurochemistry and thus was selected as the single dose (Fischer et al., 2013; Gregg et al., 2016) . The current state of knowledge supports that therapeutic effects of CTX in models of substance use disorder are likely attributed to the compound's central and not peripheral effects (Rawls et al., 2007) : 200 mg/kg in rats yields concentration in brain tissue of 3.5 µmol/l that is sufficient to upregulate GLT1 levels (Rothstein et al., 2005) .
In addition to nicotine addiction, the efficacy of β-lactam pharmacotherapies have been tested in models of psychostimulant addictions, including cocaine and synthetic cathinones, which are designer stimulant drugs that behave in mechanistically and subjectively comparable manners as cocaine (Baumann et al., 2013; Fischer et al., 2013; Kim et al., 2016a Kim et al., , 2016b Simmons et al., 2016) . Our study supports an impressive body of literature that is leading to clinical study of tolerated and nonaddictive antibiotic adjunct therapies for substance use disorders including nicotine addiction.
